CSL Of Australia Considers Doubling Seasonal Flu Vaccine Production
This article was originally published in PharmAsia News
Australia's CSL is considering production of twice the seasonal influenza vaccine it had planned for the next fiscal year. The company decided on the move after U.S. pre-season orders reserved nearly all of the production originally planned. In demand is CSL's Afluria, expected to be worth $80 million in sales in the year that begins July 1. The U.S. military is expected to be a major buyer of the batch of 9 million doses exported by CSL. A market analyst said the U.S. order might be driven by the increased flu awareness brought on by the H1N1 pandemic. (Click here for more
You may also be interested in...
PERTH, Australia - Melbourne-headquartered CSL Limited will begin clinical trials of its H1N1 influenza vaccine in healthy adults ages 18 to 64 July 22, and pediatric trials will commence Aug. 1, CSL said
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.